MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "mixed" rating to a "sell" rating.
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Reich Kristian
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Bodenstedt Matthias
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Santos da Silva Jorge
Form 8-K MoonLake Immunotherapeut For: Jan 08
Form 4 MoonLake Immunotherapeut For: Dec 19 Filed by: Reich Kristian
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.